General Information of Drug (ID: DMY84TW)

Drug Name
CVT-6883 Drug Info
Synonyms
CVT-6883; 752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 1 [1] , [2]
Cross-matching ID
PubChem CID
11270783
CAS Number
CAS 752222-83-6
TTD Drug ID
DMY84TW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [3]
Vidarabine DM0N85H Herpes simplex virus infection 1F00 Approved [3]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [4]
YT-146 DM3YVKQ Hypertension BA00-BA04 Phase 2 [5]
AB928 DMDOXMN Metastatic colorectal cancer 2B91 Phase 1/2 [6]
KF-17837 DMQ6DLZ Parkinson disease 8A00.0 Phase 1 [7]
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [8]
PBF-1129 DMOPGXM Non-small-cell lung cancer 2C25.Y Phase 1 [6]
PF-1913539 DMXEU14 Alzheimer disease 8A20 Discontinued in Phase 3 [9]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5615).
2 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
5 Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
8 Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
9 Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
10 Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 Mar 27;115(12):1581-90.